Prévisions
L'objectif de cours moyen des analystes est de 36,45 € (+33,52 %). La médiane est de 35,54 € (+30,18 %).
| Acheter |
15 |
| Conserver |
2 |
| Vendre |
0 |
Discussions dans la communauté
Il n'y a pas encore de discussion sur cet actif.
Lancer une discussionActualités Accéder au fil d'actualités
Viridian reports strong launch of Lumvoa and outlines broader TED strategy
Viridian describes the launch of Lumvoa as successful: within six weeks it reached 95% of the top 2,000 prescribing physicians, and payers indicate reimbursement levels comparable to TEPEZZA. The company is relying on existing payer infrastructure but expects delayed revenue due to authorization processes and billing rules until delivery to specialty distributors. Viridian plans a subcutaneous version (Elegrobart) with a BLA filing in Q1 2027 and is also developing programs such as a TSHR antagonist and an FcRn therapeutic program to expand the franchise. Management sees substantial untapped market potential, especially among chronic TED patients, and emphasizes market expansion rather than zero-sum competition. » Plus sur de.investing.com
Viridien reports strong order growth; stock jumps after Q2 data
Viridien’s stock rose about 14.7% after Q2 figures following a marked increase in the order backlog in geosciences to USD 306m (up 33% since March). Major project awards from IOCs and NOCs in the Gulf of Mexico, Africa and the Middle East drove the volume; analysts view this as an early sign of broader revenue recovery. The EDA segment reached an adjusted EBITDA margin of 60% and the company confirmed its full-year target of USD 100m net cash flow for 2026. Viridien also filed the interim report with the AMF, providing additional transparency and investor confidence. » Plus sur de.investing.com
Viridian Therapeutics' Lumvoa seen as differentiated treatment for thyroid eye disease, analysts raise targets
Goldman Sachs raised its target for Viridian Therapeutics to $39 and kept a Buy rating, citing Lumvoa's stronger proptosis improvement, promising safety profile and more convenient dosing versus Tepezza. Truist raised its target to $38, reiterated Buy and highlighted Lumvoa's focus on underserved markets, parity pricing and projected significant 2027 revenue with a franchise extension planned for Q1 2027. Viridian's broader pipeline includes Veligrotrug, Elegrobart, an anti‑TSHR program and FcRn inhibitors VRDN‑008 and VRDN‑006. » Plus sur finance.yahoo.com
Viridien expects markedly negative quarterly result and issues annual forecast
Viridien will release results for the quarter ended June 30, 2026 on July 30, 2026; one analyst estimates EPS for the most recent quarter at -1.81 USD per share versus 0.67 EUR a year earlier. Two analysts see quarterly revenue at 237.0 million USD versus 206.7 million EUR in the year-ago quarter. Five analysts forecast an average EPS of 9.94 USD for the current fiscal year and four analysts expect revenue averaging 1.12 billion USD (prior year 948.5 million EUR). » Plus sur finanzen.net
Viridian Therapeutics gains commercial edge after Lumvoa approval as analysts raise price targets
Following FDA approval of Lumvoa, Viridian Therapeutics priced the treatment at $450,000 per course and secured a label covering both active and chronic thyroid eye disease, which analysts say strengthens its commercial position. Wedbush raised its price target to $43 and maintained an Outperform rating, citing limited payer resistance, while Truist increased its target to $38 and reiterated a Buy rating, noting Lumvoa's convenient dosing and expected rapid adoption. Viridian plans a subcutaneous formulation with a BLA submission expected in Q1 2027 and anticipates meaningful revenue by 2027 from the underpenetrated TED market. » Plus sur finance.yahoo.com
Données financières
Au dernier trimestre, Viridian Therapeutics Aktie a réalisé un chiffre d'affaires de 22,74 M € et un bénéfice net de -89,35 M €
| (EUR) | septembre 2026 | YoY |
|---|---|---|
| Chiffre d'affaires | 22,74 M | 62,19 % |
| Bénéfice brut | 21,39 M | 64,43 % |
| Bénéfice net | -89,35 M | 203,07 % |
| EBITDA | -89,28 M | 208,81 % |
Données fondamentales
| Indicateur | Valeur |
|---|---|
Capitalisation boursière | 3,1 Md € |
Nombre d'actions | 113,56 M |
Plus haut/bas sur 52 semaines | 31,25 € - 12,01 € |
| Dividendes | Non |
Bêta | 0,96 |
Ratio P/E | -7,74 |
Ratio PEG | 0,42 |
Ratio P/B | 5,85 |
Ratio P/S | 129,32 |
Profil de l'entreprise
Viridian Therapeutics, Inc., une entreprise de biotechnologie, développe des traitements destinés aux patients atteints de maladies graves. Elle développe le VRDN-001, un anticorps monoclonal humanisé anti-IGF-1R en essai clinique de phase 1/2 pour le traitement de l'ophtalmopathie thyroïdienne (TED) ; le VRDN-002, un anticorps anti-IGF-1R, en essai clinique de phase 1 ; et le VRDN-003, un anticorps thérapeutique ciblant l'IGF-1R pour le traitement de la TED. La société était auparavant connue sous le nom de Miragen Therapeutics, Inc. et a changé de nom pour devenir Viridian Therapeutics, Inc. en janvier 2021. Viridian Therapeutics, Inc. a été fondée en 2006 et son siège social se trouve à Waltham, dans le Massachusetts.
| Nom | Viridian Therapeutics Aktie |
| PDG | Stephen F. Mahoney |
| Siège social | Waltham,
ma États-Unis |
| Site web | |
| Secteur | Santé |
| Industrie | Équipements et fournitures médicaux |
| Introduction en bourse | 18/06/2014 |
| Employés | 252 |
Symboles boursiers
| Bourse | Symbole |
|---|---|
NASDAQ | VRDN |
London Stock Exchange | 0K1R.L |
Frankfurt | 1S1.F |
Düsseldorf | 1S1.DU |
London | 0K1R.L |